COVAG study - COVID 19 Antigen Study

Completed

• Conditions: Covid-19; U07.1; COVID-19, virus identified

• Registration Number: DRKS00026956
• Lead Sponsor: Synlab Academy, Synlab Holding Deutschland GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-22
• Study Completion: 2022-03-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 3733

Inclusion Criteria

Subjects eligible for inclusion in this study must meet the following criteria:
1. Signed informed consent must be obtained prior to study participation. The patient must be capable of understanding the nature, significance and implication of the trial.
2. Age 18 years or more

Exclusion Criteria

1. Lack of informed consent
2. Inability to understand the nature, significance and implication of the trial.
3. Severe clinical conditions requiring emergency hospitalization
4. Children and adolescents under the age of 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sensitivity and specificity of SARS-CoV-2 rapid detection tests. 31.03.2021.

Secondary Outcome Measures

Name	Time	Method
Sensitivity of rapid detection tests for different SARS-CoV-2 variants. 31.12.2021.